

Updated: 07/2025 Approved: 07/2025

Request for Prior Authorization for ALS Medication: Qalsody (tofersen)
Website Form – <a href="https://www.wv.highmarkhealthoptions.com">www.wv.highmarkhealthoptions.com</a>
Submit request via: Fax - 1-833-547-2030

All requests for the ALS Medication: Qalsody (tofersen) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of **amyotropic lateral sclerosis (ALS)** and the following criteria is met:

- Must be prescribed by or in consultation with a neurologist
- Must have a mutation in the superoxide dismutase 1 (SODI) gene
- Provide an ALSFRS-R (Revised ALS functional rating scale) score within the past 6 months
- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 6 months
- Reauthorization criteria:
  - o Continues to experience clinical benefit based on the prescriber's assessment
  - o Provide an ALSFRS-R score within the past 12 months
- Reauthorization Duration of Approval: 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.



Updated: 07/2025 Approved: 07/2025

## ALS MEDICATION: QALSODY PRIOR AUTHORIZATION FORM

Please complete and fax all requested	d information below includin	g any progress notes, l	aboratory test results, or chart documentation	
as applicable to Highmark Health Options Pharmacy Services. FAX: (833)-547-2030				
If needed, you may call to speak to a Pharmacy Services Representative. PHONE: (844) 325-6251 Mon – Fri 8 am to 7 pm				
PROVIDER INFORMATION				
Requesting Provider:			NPI:	
Provider Specialty:			Office Contact:	
Office Address:			Office Phone:	
Office Fax:  MEMBER INFORMATION				
Member Name: DOB:				
		Member weight:	er weight: Height:	
REQUESTED DRUG INFORMATION				
Medication: Strength:				
Directions:			Quantity: Refills:	
Is the member currently receiving requested medication? Yes			Medication Initiated:	
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the				
patient? Yes No				
Billing Information				
This medication will be billed: at a pharmacy OR medically, JCODE:				
Place of Service: Hospital Provider's office Member's home Other				
Place of Service Information				
Name: NPI:				
Address:		Phone:	Phone:	
MEDICAL HISTORY (Complete for ALL requests)				
Diagnosis: ICD Code:				
ALSFRS-R Score:				
Is there a mutation in the <i>SOD1</i> gene?  Yes  No				
CURRENT or PREVIOUS THERAPY				
Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)	
	DEALITH	ODIZATION		
REAUTHORIZATION  Has the member experienced clinical benefit with treatment? Yes No				
ALSFRS-R Score:				
SUPPORTING INFORMATION or CLINICAL RATIONALE				
SOLI OKLING IN TOKUMITON OF CERTICAL KATTOWALL				
Prescribing Provider Signature Date				
	5			